DNMT1 and head and neck squamous cell carcinoma: Regarding DNMT inhibitors, a phase-I trial of the use of the DNMT inhibitor azacytidine as neoadjuvant monotherapy, involving a phase-IB trial of decitabine monotherapy, is currently underway in patients with HPV-positive HNSCC.